Please login to the form below

Not currently logged in
Email:
Password:

Aesica creates commercial MD role

Appoints Catalent’s Ian Muir to new position

Aesica has named Ian Muir as the company's first commercial managing director, effective February 24.

The contract development and manufacturing (CDMO) firm Aesica said the creation of the role reflects the company's decision to focus on 'core commercial activities'.

Muir's responsibilities will cover manufacture of active pharmaceutical ingredients, formulation development and formulated products, while he will also lead the expansion of the business into new markets, such as China and Japan.

He joins from the CDMO Catalent where he was responsible for the global provision of contract development and manufacturing services for oral dose forms.

Muir's previous experience also includes commercial responsibilities in the US, Australia and Japan.

Aesica's CEO Robert Hardy said: “Ian brings strong commercial business knowledge and has proven experience of delivering growth and will play a pivotal role in driving further business growth for Aesica across API, formulation development and formulated products.”

5th February 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics